vs

Side-by-side financial comparison of FATE THERAPEUTICS INC (FATE) and GENERATION INCOME PROPERTIES, INC. (GIPR). Click either name above to swap in a different company.

GENERATION INCOME PROPERTIES, INC. is the larger business by last-quarter revenue ($2.5M vs $1.4M, roughly 1.8× FATE THERAPEUTICS INC). On growth, GENERATION INCOME PROPERTIES, INC. posted the faster year-over-year revenue change (-8.0% vs -26.4%). Over the past eight quarters, GENERATION INCOME PROPERTIES, INC.'s revenue compounded faster (0.5% CAGR vs -15.7%).

Insys Therapeutics was an American specialty pharmaceutical company based in Chandler, Arizona in 1990. Its main product was Subsys, a sublingual liquid form of the drug fentanyl. Fentanyl is an extremely fast-acting and powerful opioid used to relieve breakthrough pain in cancer patients, and prescription of fentanyl in the US for such pain usually requires documented failure of more conservative therapies.

Emaar Properties is an Emirati real estate development company located in the United Arab Emirates. The two largest shareholders are Dubai ruler Mohammed bin Rashid Al Maktoum and the UAE's sovereign wealth fund Investment Corporation of Dubai.

FATE vs GIPR — Head-to-Head

Bigger by revenue
GIPR
GIPR
1.8× larger
GIPR
$2.5M
$1.4M
FATE
Growing faster (revenue YoY)
GIPR
GIPR
+18.4% gap
GIPR
-8.0%
-26.4%
FATE
Faster 2-yr revenue CAGR
GIPR
GIPR
Annualised
GIPR
0.5%
-15.7%
FATE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FATE
FATE
GIPR
GIPR
Revenue
$1.4M
$2.5M
Net Profit
$-359.5K
Gross Margin
Operating Margin
-58.6%
Net Margin
-14.6%
Revenue YoY
-26.4%
-8.0%
Net Profit YoY
37.9%
-22.7%
EPS (diluted)
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FATE
FATE
GIPR
GIPR
Q4 25
$1.4M
$2.5M
Q3 25
$1.7M
$2.5M
Q2 25
$1.9M
$2.4M
Q1 25
$1.6M
$2.4M
Q4 24
$1.9M
$2.7M
Q3 24
$3.1M
$2.4M
Q2 24
$6.8M
$2.3M
Q1 24
$1.9M
$2.4M
Net Profit
FATE
FATE
GIPR
GIPR
Q4 25
$-359.5K
Q3 25
$-32.3M
$-2.8M
Q2 25
$-34.1M
$-4.4M
Q1 25
$-37.6M
$-2.7M
Q4 24
$-292.9K
Q3 24
$-47.7M
$-3.0M
Q2 24
$-38.4M
$-2.3M
Q1 24
$-48.0M
$-2.8M
Operating Margin
FATE
FATE
GIPR
GIPR
Q4 25
-58.6%
Q3 25
-1995.1%
-68.8%
Q2 25
-1938.5%
-97.6%
Q1 25
-2534.1%
-62.0%
Q4 24
-40.9%
Q3 24
-1703.9%
-57.1%
Q2 24
-665.7%
-65.1%
Q1 24
-2652.9%
-49.3%
Net Margin
FATE
FATE
GIPR
GIPR
Q4 25
-14.6%
Q3 25
-1852.4%
-114.4%
Q2 25
-1786.6%
-181.8%
Q1 25
-2309.5%
-114.7%
Q4 24
-11.0%
Q3 24
-1551.0%
-123.7%
Q2 24
-567.4%
-100.1%
Q1 24
-2493.7%
-116.1%
EPS (diluted)
FATE
FATE
GIPR
GIPR
Q4 25
$-0.17
Q3 25
$-0.27
$-0.52
Q2 25
$-0.29
$-0.81
Q1 25
$-0.32
$-0.50
Q4 24
$0.00
Q3 24
$-0.40
$-0.55
Q2 24
$-0.33
$-0.42
Q1 24
$-0.47
$-0.67

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FATE
FATE
GIPR
GIPR
Cash + ST InvestmentsLiquidity on hand
$203.7M
$6.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$207.2M
$-4.2M
Total Assets
$318.9M
$97.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FATE
FATE
GIPR
GIPR
Q4 25
$203.7M
$6.2M
Q3 25
$215.4M
$247.3K
Q2 25
$222.8M
$356.1K
Q1 25
$240.4M
$630.6K
Q4 24
$279.1M
$612.9K
Q3 24
$296.9M
$1.5M
Q2 24
$304.9M
$2.6M
Q1 24
$121.3M
$1.7M
Stockholders' Equity
FATE
FATE
GIPR
GIPR
Q4 25
$207.2M
$-4.2M
Q3 25
$234.1M
$-3.9M
Q2 25
$261.4M
$-1.4M
Q1 25
$288.4M
$3.1M
Q4 24
$318.7M
$5.8M
Q3 24
$362.3M
$6.2M
Q2 24
$397.0M
$9.1M
Q1 24
$426.1M
$11.9M
Total Assets
FATE
FATE
GIPR
GIPR
Q4 25
$318.9M
$97.3M
Q3 25
$343.7M
$103.4M
Q2 25
$371.6M
$105.0M
Q1 25
$398.7M
$116.7M
Q4 24
$440.7M
$106.6M
Q3 24
$495.0M
$108.0M
Q2 24
$528.8M
$104.5M
Q1 24
$569.9M
$104.6M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FATE
FATE
GIPR
GIPR
Operating Cash FlowLast quarter
$-106.1M
$929.5K
Free Cash FlowOCF − Capex
$-112.0M
FCF MarginFCF / Revenue
-8183.9%
Capex IntensityCapex / Revenue
434.8%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-199.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FATE
FATE
GIPR
GIPR
Q4 25
$-106.1M
$929.5K
Q3 25
$-24.4M
$935.4K
Q2 25
$-24.6M
$-1.2M
Q1 25
$-33.8M
$718.2K
Q4 24
$-122.9M
$1.0M
Q3 24
$-29.4M
$556.9K
Q2 24
$-32.3M
$200.6K
Q1 24
$-33.4M
$26.0K
Free Cash Flow
FATE
FATE
GIPR
GIPR
Q4 25
$-112.0M
Q3 25
$-26.6M
Q2 25
$-25.9M
Q1 25
$-35.0M
Q4 24
$-123.6M
$-4.8M
Q3 24
$-29.9M
$-5.4M
Q2 24
$-32.4M
Q1 24
$-33.4M
FCF Margin
FATE
FATE
GIPR
GIPR
Q4 25
-8183.9%
Q3 25
-1526.5%
Q2 25
-1360.7%
Q1 25
-2148.9%
Q4 24
-6645.4%
-177.9%
Q3 24
-973.1%
-225.1%
Q2 24
-477.8%
Q1 24
-1736.9%
Capex Intensity
FATE
FATE
GIPR
GIPR
Q4 25
434.8%
0.0%
Q3 25
126.5%
Q2 25
71.4%
Q1 25
73.4%
Q4 24
39.2%
216.2%
Q3 24
16.1%
248.3%
Q2 24
0.8%
Q1 24
4.5%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons